The FDA told physicians that prescribing fluoroquinolones to treat bacterial infections in patients with diabetes poses a serious health risk and said it is requiring label and medication guide changes due to the possibility of permanent nerve damage. A study in the journal Clinical Infectious Diseases showed diabetes patients on fluoroquinolones had a higher risk of severe dysglycemia compared with those taking macrolides or cephalosporins, and that moxifloxacin appeared to have the greatest risk.

Full Story:

Related Summaries